Cardiol Therapeutics Inc. (CRDL) 10-Year Financial Performance & Capital Metrics

CRDL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

AboutCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.Show more

Revenue $0
EBITDA -$40M -80.0%
Net Income -$37M -72.8%
EPS (Diluted) -0.51 -15.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -138.47% -117.8%
ROIC -
Debt/Equity 0.01 +3.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 11.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.9%

ROCE

10Y Avg-77.9%

5Y Avg-90.98%

3Y Avg-90.5%

Latest-151.25%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	62.27K	0	0	0
Revenue Growth %	-	-	-	-	-	-1%	-	-
Cost of Goods Sold+	53.34K	91.49K	116.11K	180.17K	174.26K	162.23K	187.38K	0
COGS % of Revenue	-	-	-	-	2.8%	-	-	-
Gross Profit+	-53.34K	-91.49K	-116.11K	-180.17K	-112K	-162.23K	-187.38K	0
Gross Margin %	-	-	-	-	-1.8%	-	-	-
Gross Profit Growth %	-	-0.72%	-0.27%	-0.55%	0.38%	-0.45%	-0.16%	1%
Operating Expenses+	1.6M	7.49M	10.78M	16.06M	30.46M	30.33M	22.29M	40.28M
OpEx % of Revenue	-	-	-	-	489.13%	-	-	-
Selling, General & Admin	1.1M	5.87M	8.06M	7.81M	21.86M	16.34M	11.55M	26.26M
SG&A % of Revenue	-	-	-	-	351.1%	-	-	-
Research & Development	441.26K	1.53M	2.72M	8.25M	8.59M	13.99M	10.73M	14.01M
R&D % of Revenue	-	-	-	-	138.02%	-	-	-
Other Operating Expenses	-60.56K	0	0	0	0	0	0	0
Operating Income+	-1.59M	-7.39M	-10.89M	-16.24M	-30.57M	-30.49M	-22.47M	-40.28M
Operating Margin %	-	-	-	-	-490.92%	-	-	-
Operating Income Growth %	-	-3.65%	-0.47%	-0.49%	-0.88%	0%	0.26%	-0.79%
EBITDA+	-1.54M	-7.3M	-10.78M	-16.06M	-30.39M	-30.33M	-22.29M	-40.11M
EBITDA Margin %	-	-	-	-	-488.13%	-	-	-
EBITDA Growth %	-	-3.75%	-0.48%	-0.49%	-0.89%	0%	0.27%	-0.8%
D&A (Non-Cash Add-back)	53.34K	91.49K	116.11K	180.17K	174.26K	162.23K	187.38K	162.1K
EBIT	-1.56M	-6.58M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-40.28M
Net Interest Income+	-54.44K	-560.07K	188.78K	60.11K	106K	1.24M	2.04M	1.19M
Interest Income	6.12K	103.31K	245.42K	60.11K	106K	1.24M	2.04M	1.19M
Interest Expense	60.56K	663.37K	621	-	0	0	0	0
Other Income/Expense	-71.61K	-8.5M	342.2K	38.87K	5.56M	7.68M	1.25M	3.6M
Pretax Income+	-1.66M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Pretax Margin %	-	-	-	-	-401.71%	-	-	-
Income Tax+	60.56K	663.37K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.66M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Net Margin %	-	-	-	-	-401.71%	-	-	-
Net Income Growth %	-	-8.57%	0.34%	-0.54%	-0.54%	0.09%	0.07%	-0.73%
Net Income (Continuing)	-1.81M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.07	-0.66	-0.53	-0.69	-0.73	-0.49	-0.44	-0.51
EPS Growth %	-	-8.03%	0.2%	-0.3%	-0.06%	0.33%	0.1%	-0.16%
EPS (Basic)	-0.07	-0.66	-0.53	-0.69	-0.73	-0.49	-0.44	-0.51
Diluted Shares Outstanding	22.71M	24.2M	25.82M	29.86M	43.22M	62.51M	64.46M	71.57M
Basic Shares Outstanding	22.71M	24.2M	25.82M	29.86M	43.22M	62.51M	64.46M	71.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.48M	24.03M	14.37M	14.95M	87.14M	45.32M	36.15M	31.67M
Cash & Short-Term Investments	2.36M	16.73M	6.96M	14.03M	83.9M	43.87M	34.93M	30.58M
Cash Only	2.36M	16.73M	6.96M	14.03M	83.9M	43.83M	34.93M	30.58M
Short-Term Investments	0	0	0	0	0	45.65K	0	0
Accounts Receivable	101.75K	460.78K	0	0	65.74K	354.24K	0	361.62K
Days Sales Outstanding	-	-	-	-	385.35	-	-	-
Inventory	0	6.35M	6.2M	357.02K	0	0	0	0
Days Inventory Outstanding	-	25.31K	19.5K	723.27	-	-	-	-
Other Current Assets	0	0	927.87K	219.92K	341.39K	0	279.87K	0
Total Non-Current Assets+	735.83K	658.13K	1.13M	943.24K	735.74K	435.64K	547.42K	195.59K
Property, Plant & Equipment	18.81K	25.55K	584.05K	479.55K	356.49K	218.16K	337.06K	195.59K
Fixed Asset Turnover	-	-	-	-	0.17x	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	717.02K	632.58K	548.13K	463.69K	379.25K	217.47K	210.36K	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	3.22M	24.68M	15.5M	15.89M	87.88M	45.76M	36.7M	31.86M
Asset Turnover	-	-	-	-	0.00x	-	-	-
Asset Growth %	-	6.66%	-0.37%	0.03%	4.53%	-0.48%	-0.2%	-0.13%
Total Current Liabilities+	176.71K	2.14M	690.55K	2.52M	11.57M	7.23M	8.3M	7.01M
Accounts Payable	165.41K	1.99M	561.29K	1.77M	4.14M	6.16M	7.62M	6.98M
Days Payables Outstanding	1.13K	7.93K	1.76K	3.59K	8.67K	13.86K	14.85K	-
Short-Term Debt	0	0	0	0	0	37.21K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	11.3K	153.89K	0	0	6.66M	1.04M	238.18K	0
Current Ratio	14.06x	11.22x	20.81x	5.94x	7.53x	6.27x	4.36x	4.52x
Quick Ratio	14.06x	8.26x	11.83x	5.80x	7.53x	6.27x	4.36x	4.52x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	190.04K	269.22K	140.28K	104.65K	72.87K	16.54K	158.53K	125.52K
Long-Term Debt	190.04K	269.22K	0	0	0	0	0	0
Capital Lease Obligations	0	0	140.28K	104.65K	72.87K	16.54K	158.53K	125.52K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	366.76K	2.41M	830.83K	2.62M	11.64M	7.25M	8.45M	7.14M
Total Debt+	190.04K	269.22K	190.75K	156.57K	117.58K	53.76K	174.34K	158.53K
Net Debt	-2.17M	-16.46M	-6.77M	-13.87M	-83.78M	-43.77M	-34.76M	-30.42M
Debt / Equity	0.07x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-26.24x	-11.14x	-17543.88x	-	-	-	-	-
Total Equity+	2.85M	22.27M	14.67M	13.27M	76.24M	38.51M	28.25M	24.73M
Equity Growth %	-	6.8%	-0.34%	-0.1%	4.74%	-0.49%	-0.27%	-0.12%
Book Value per Share	0.13	0.92	0.57	0.44	1.76	0.62	0.44	0.35
Total Shareholders' Equity	2.85M	22.27M	14.67M	13.27M	76.24M	38.51M	28.25M	24.73M
Common Stock	4.26M	36.72M	39.41M	51.92M	142.92M	108.84M	148.52M	179.34M
Retained Earnings	-1.66M	-17.55M	-31.24M	-51.88M	-83.52M	-84.43M	-142.58M	-179.25M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	259.46K	1.85M	1.73M	4.46M	4.18M	2.6M	3.52M	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.29M	-10.89M	-11.38M	-9.13M	-23.55M	-27.22M	-25.18M	-25.06M
Operating CF Margin %	-	-	-	-	-378.22%	-	-	-
Operating CF Growth %	-	-7.43%	-0.04%	0.2%	-1.58%	-0.16%	0.07%	0%
Net Income	-1.66M	-15.89M	-13.68M	-20.64M	-31.64M	-30.93M	-28.13M	-36.68M
Depreciation & Amortization	53.34K	91.49K	150.57K	229.54K	220.42K	219.91K	248.35K	373.11K
Stock-Based Compensation	237	1.65M	3.27M	2.77M	8.5M	5.01M	4.16M	14.28M
Deferred Taxes	0	7.88M	0	0	-4.92M	-9.16M	0	0
Other Non-Cash Items	267.01K	574.86K	507.74K	201.02K	4.21M	1.89M	-911.39K	-2.1M
Working Capital Changes	48.38K	-5.2M	-1.62M	8.32M	76.52K	5.75M	-545.88K	-931.57K
Change in Receivables	-101.75K	-359.03K	-467.09K	707.95K	-59.95K	-144.18K	200.32K	-81.75K
Change in Inventory	0	-6.35K	142.58K	1.1M	17.97K	-4.47M	0	0
Change in Payables	176.71K	1.96M	467.09K	0	2.39M	4.47M	0	0
Cash from Investing+	-29.17K	-13.79K	-424.31K	-40.6K	-12.92K	-74.71K	-64.31K	-21.29K
Capital Expenditures	-29.17K	-13.79K	-424.31K	-40.6K	-12.92K	-74.71K	-64.31K	-21.29K
CapEx % of Revenue	-	-	-	-	0.21%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-7.23K	0	0	0	0	0	0	0
Cash from Financing+	3.68M	25.28M	2.03M	16.3M	93.44M	-53.93K	-55.38K	18.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	-120.55K	-1.02M	382.15K	-904.51K	9.41M	0	0	-2.47M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.32M	-10.91M	-11.8M	-9.17M	-23.56M	-27.3M	-25.24M	-25.08M
FCF Margin %	-	-	-	-	-378.43%	-	-	-
FCF Growth %	-	-7.25%	-0.08%	0.22%	-1.57%	-0.16%	0.08%	0.01%
FCF per Share	-0.06	-0.45	-0.46	-0.31	-0.55	-0.44	-0.39	-0.35
FCF Conversion (FCF/Net Income)	0.78x	0.69x	1.08x	0.56x	0.94x	1.19x	1.19x	0.68x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.2%	-126.5%	-57.12%	-115.96%	-55.89%	-39.77%	-63.58%	-138.47%
Return on Invested Capital (ROIC)	-173.39%	-170.57%	-119.13%	-333.33%	-	-	-	-
Gross Margin	-	-	-	-	-179.87%	-	-	-
Net Margin	-	-	-	-	-40170.87%	-	-	-
Debt / Equity	0.07x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x
Interest Coverage	-26.24x	-11.14x	-17543.88x	-	-	-	-	-
FCF Conversion	0.78x	0.69x	1.08x	0.56x	0.94x	1.19x	1.19x	0.68x
Revenue Growth	-	-	-	-	-	-100%	-	-

Frequently Asked Questions

Growth & Financials

Cardiol Therapeutics Inc. (CRDL) grew revenue by 0.0% over the past year. Growth has been modest.

Cardiol Therapeutics Inc. (CRDL) reported a net loss of $32.3M for fiscal year 2024.

Dividend & Returns

Cardiol Therapeutics Inc. (CRDL) has a return on equity (ROE) of -138.5%. Negative ROE indicates the company is unprofitable.

Cardiol Therapeutics Inc. (CRDL) had negative free cash flow of $24.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Cardiol Therapeutics Inc. (CRDL) 10-Year Financial Performance & Capital Metrics

CRDL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

Revenue $0
EBITDA -$40M -80.0%
Net Income -$37M -72.8%
EPS (Diluted) -0.51 -15.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -138.47% -117.8%
ROIC -
Debt/Equity 0.01 +3.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 11.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.9%

ROCE

10Y Avg-77.9%

5Y Avg-90.98%

3Y Avg-90.5%

Latest-151.25%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	62.27K	0	0	0
Revenue Growth %	-	-	-	-	-	-1%	-	-
Cost of Goods Sold+	53.34K	91.49K	116.11K	180.17K	174.26K	162.23K	187.38K	0
COGS % of Revenue	-	-	-	-	2.8%	-	-	-
Gross Profit+	-53.34K	-91.49K	-116.11K	-180.17K	-112K	-162.23K	-187.38K	0
Gross Margin %	-	-	-	-	-1.8%	-	-	-
Gross Profit Growth %	-	-0.72%	-0.27%	-0.55%	0.38%	-0.45%	-0.16%	1%
Operating Expenses+	1.6M	7.49M	10.78M	16.06M	30.46M	30.33M	22.29M	40.28M
OpEx % of Revenue	-	-	-	-	489.13%	-	-	-
Selling, General & Admin	1.1M	5.87M	8.06M	7.81M	21.86M	16.34M	11.55M	26.26M
SG&A % of Revenue	-	-	-	-	351.1%	-	-	-
Research & Development	441.26K	1.53M	2.72M	8.25M	8.59M	13.99M	10.73M	14.01M
R&D % of Revenue	-	-	-	-	138.02%	-	-	-
Other Operating Expenses	-60.56K	0	0	0	0	0	0	0
Operating Income+	-1.59M	-7.39M	-10.89M	-16.24M	-30.57M	-30.49M	-22.47M	-40.28M
Operating Margin %	-	-	-	-	-490.92%	-	-	-
Operating Income Growth %	-	-3.65%	-0.47%	-0.49%	-0.88%	0%	0.26%	-0.79%
EBITDA+	-1.54M	-7.3M	-10.78M	-16.06M	-30.39M	-30.33M	-22.29M	-40.11M
EBITDA Margin %	-	-	-	-	-488.13%	-	-	-
EBITDA Growth %	-	-3.75%	-0.48%	-0.49%	-0.89%	0%	0.27%	-0.8%
D&A (Non-Cash Add-back)	53.34K	91.49K	116.11K	180.17K	174.26K	162.23K	187.38K	162.1K
EBIT	-1.56M	-6.58M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-40.28M
Net Interest Income+	-54.44K	-560.07K	188.78K	60.11K	106K	1.24M	2.04M	1.19M
Interest Income	6.12K	103.31K	245.42K	60.11K	106K	1.24M	2.04M	1.19M
Interest Expense	60.56K	663.37K	621	-	0	0	0	0
Other Income/Expense	-71.61K	-8.5M	342.2K	38.87K	5.56M	7.68M	1.25M	3.6M
Pretax Income+	-1.66M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Pretax Margin %	-	-	-	-	-401.71%	-	-	-
Income Tax+	60.56K	663.37K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.66M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Net Margin %	-	-	-	-	-401.71%	-	-	-
Net Income Growth %	-	-8.57%	0.34%	-0.54%	-0.54%	0.09%	0.07%	-0.73%
Net Income (Continuing)	-1.81M	-15.89M	-10.55M	-16.2M	-25.01M	-22.82M	-21.22M	-36.68M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.07	-0.66	-0.53	-0.69	-0.73	-0.49	-0.44	-0.51
EPS Growth %	-	-8.03%	0.2%	-0.3%	-0.06%	0.33%	0.1%	-0.16%
EPS (Basic)	-0.07	-0.66	-0.53	-0.69	-0.73	-0.49	-0.44	-0.51
Diluted Shares Outstanding	22.71M	24.2M	25.82M	29.86M	43.22M	62.51M	64.46M	71.57M
Basic Shares Outstanding	22.71M	24.2M	25.82M	29.86M	43.22M	62.51M	64.46M	71.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.48M	24.03M	14.37M	14.95M	87.14M	45.32M	36.15M	31.67M
Cash & Short-Term Investments	2.36M	16.73M	6.96M	14.03M	83.9M	43.87M	34.93M	30.58M
Cash Only	2.36M	16.73M	6.96M	14.03M	83.9M	43.83M	34.93M	30.58M
Short-Term Investments	0	0	0	0	0	45.65K	0	0
Accounts Receivable	101.75K	460.78K	0	0	65.74K	354.24K	0	361.62K
Days Sales Outstanding	-	-	-	-	385.35	-	-	-
Inventory	0	6.35M	6.2M	357.02K	0	0	0	0
Days Inventory Outstanding	-	25.31K	19.5K	723.27	-	-	-	-
Other Current Assets	0	0	927.87K	219.92K	341.39K	0	279.87K	0
Total Non-Current Assets+	735.83K	658.13K	1.13M	943.24K	735.74K	435.64K	547.42K	195.59K
Property, Plant & Equipment	18.81K	25.55K	584.05K	479.55K	356.49K	218.16K	337.06K	195.59K
Fixed Asset Turnover	-	-	-	-	0.17x	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	717.02K	632.58K	548.13K	463.69K	379.25K	217.47K	210.36K	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	3.22M	24.68M	15.5M	15.89M	87.88M	45.76M	36.7M	31.86M
Asset Turnover	-	-	-	-	0.00x	-	-	-
Asset Growth %	-	6.66%	-0.37%	0.03%	4.53%	-0.48%	-0.2%	-0.13%
Total Current Liabilities+	176.71K	2.14M	690.55K	2.52M	11.57M	7.23M	8.3M	7.01M
Accounts Payable	165.41K	1.99M	561.29K	1.77M	4.14M	6.16M	7.62M	6.98M
Days Payables Outstanding	1.13K	7.93K	1.76K	3.59K	8.67K	13.86K	14.85K	-
Short-Term Debt	0	0	0	0	0	37.21K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	11.3K	153.89K	0	0	6.66M	1.04M	238.18K	0
Current Ratio	14.06x	11.22x	20.81x	5.94x	7.53x	6.27x	4.36x	4.52x
Quick Ratio	14.06x	8.26x	11.83x	5.80x	7.53x	6.27x	4.36x	4.52x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	190.04K	269.22K	140.28K	104.65K	72.87K	16.54K	158.53K	125.52K
Long-Term Debt	190.04K	269.22K	0	0	0	0	0	0
Capital Lease Obligations	0	0	140.28K	104.65K	72.87K	16.54K	158.53K	125.52K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	366.76K	2.41M	830.83K	2.62M	11.64M	7.25M	8.45M	7.14M
Total Debt+	190.04K	269.22K	190.75K	156.57K	117.58K	53.76K	174.34K	158.53K
Net Debt	-2.17M	-16.46M	-6.77M	-13.87M	-83.78M	-43.77M	-34.76M	-30.42M
Debt / Equity	0.07x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-26.24x	-11.14x	-17543.88x	-	-	-	-	-
Total Equity+	2.85M	22.27M	14.67M	13.27M	76.24M	38.51M	28.25M	24.73M
Equity Growth %	-	6.8%	-0.34%	-0.1%	4.74%	-0.49%	-0.27%	-0.12%
Book Value per Share	0.13	0.92	0.57	0.44	1.76	0.62	0.44	0.35
Total Shareholders' Equity	2.85M	22.27M	14.67M	13.27M	76.24M	38.51M	28.25M	24.73M
Common Stock	4.26M	36.72M	39.41M	51.92M	142.92M	108.84M	148.52M	179.34M
Retained Earnings	-1.66M	-17.55M	-31.24M	-51.88M	-83.52M	-84.43M	-142.58M	-179.25M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	259.46K	1.85M	1.73M	4.46M	4.18M	2.6M	3.52M	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.29M	-10.89M	-11.38M	-9.13M	-23.55M	-27.22M	-25.18M	-25.06M
Operating CF Margin %	-	-	-	-	-378.22%	-	-	-
Operating CF Growth %	-	-7.43%	-0.04%	0.2%	-1.58%	-0.16%	0.07%	0%
Net Income	-1.66M	-15.89M	-13.68M	-20.64M	-31.64M	-30.93M	-28.13M	-36.68M
Depreciation & Amortization	53.34K	91.49K	150.57K	229.54K	220.42K	219.91K	248.35K	373.11K
Stock-Based Compensation	237	1.65M	3.27M	2.77M	8.5M	5.01M	4.16M	14.28M
Deferred Taxes	0	7.88M	0	0	-4.92M	-9.16M	0	0
Other Non-Cash Items	267.01K	574.86K	507.74K	201.02K	4.21M	1.89M	-911.39K	-2.1M
Working Capital Changes	48.38K	-5.2M	-1.62M	8.32M	76.52K	5.75M	-545.88K	-931.57K
Change in Receivables	-101.75K	-359.03K	-467.09K	707.95K	-59.95K	-144.18K	200.32K	-81.75K
Change in Inventory	0	-6.35K	142.58K	1.1M	17.97K	-4.47M	0	0
Change in Payables	176.71K	1.96M	467.09K	0	2.39M	4.47M	0	0
Cash from Investing+	-29.17K	-13.79K	-424.31K	-40.6K	-12.92K	-74.71K	-64.31K	-21.29K
Capital Expenditures	-29.17K	-13.79K	-424.31K	-40.6K	-12.92K	-74.71K	-64.31K	-21.29K
CapEx % of Revenue	-	-	-	-	0.21%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-7.23K	0	0	0	0	0	0	0
Cash from Financing+	3.68M	25.28M	2.03M	16.3M	93.44M	-53.93K	-55.38K	18.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	-120.55K	-1.02M	382.15K	-904.51K	9.41M	0	0	-2.47M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.32M	-10.91M	-11.8M	-9.17M	-23.56M	-27.3M	-25.24M	-25.08M
FCF Margin %	-	-	-	-	-378.43%	-	-	-
FCF Growth %	-	-7.25%	-0.08%	0.22%	-1.57%	-0.16%	0.08%	0.01%
FCF per Share	-0.06	-0.45	-0.46	-0.31	-0.55	-0.44	-0.39	-0.35
FCF Conversion (FCF/Net Income)	0.78x	0.69x	1.08x	0.56x	0.94x	1.19x	1.19x	0.68x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.2%	-126.5%	-57.12%	-115.96%	-55.89%	-39.77%	-63.58%	-138.47%
Return on Invested Capital (ROIC)	-173.39%	-170.57%	-119.13%	-333.33%	-	-	-	-
Gross Margin	-	-	-	-	-179.87%	-	-	-
Net Margin	-	-	-	-	-40170.87%	-	-	-
Debt / Equity	0.07x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x
Interest Coverage	-26.24x	-11.14x	-17543.88x	-	-	-	-	-
FCF Conversion	0.78x	0.69x	1.08x	0.56x	0.94x	1.19x	1.19x	0.68x
Revenue Growth	-	-	-	-	-	-100%	-	-

Frequently Asked Questions

Growth & Financials

Cardiol Therapeutics Inc. (CRDL) grew revenue by 0.0% over the past year. Growth has been modest.

Cardiol Therapeutics Inc. (CRDL) reported a net loss of $32.3M for fiscal year 2024.

Dividend & Returns

Cardiol Therapeutics Inc. (CRDL) has a return on equity (ROE) of -138.5%. Negative ROE indicates the company is unprofitable.

Cardiol Therapeutics Inc. (CRDL) had negative free cash flow of $24.3M in fiscal year 2024, likely due to heavy capital investments.